Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
- A recent estimate of the annual incidence of traumatic spinal cord injury (CCI) is approximately 54 cases per one million people in the United States.
- The estimated number of people with tSCI living in the United States is approximately 302,000 persons, ranging from 255,000 to 383,000 persons.
- The average age at injury has increased from 29 during the 1970s to 43 since 2015.
- Traumatic brain injury (TBI) is defined as an alteration in brain function or other evidence of brain pathology caused by an external force. Examples of TBI include falls, assaults, motor vehicle accidents and sports injuries.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
- Tax credits for qualified clinical trials
- Exemption from user fees
- Potential for seven years of market exclusivity after approval
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
| Stock stats Jan 5 2024 | |
| 52 Week Range | 0.1000 0.4200 |
| Volume | 7,000 |
| Avg. Volume | 4,511 |
| Market Cap | 14.475M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.01 |
| In-depth Corporate Presentation Litchfield Research |
August 19th
Marc CHALLANDE
Fandifi (CSE: FDM) (OTCQB: FDMSF) (FSE: TQ4) hosted on August 11 a live corporate webinar and introduced fan engagement technology. It is time to bring more details about how exciting the company is. Fandifi is building a crowd-based and system-generated prediction fan engagement platform. The Fandifi platform runs on an associated neural network tailor-made for content creators to increase the Gamification of their content and enable fan engagement within their communities regardless of distribution.
Company Overview
Fandifi helps to bring engagement. Indeed the company empowers global content creators with a unique crowd-based and system-generated prediction engine that increases fan engagement and satisfaction through unique content. The company can expand into every industry with fans, including movies, music, live events, fashion, food, and more. About Fandifi’s timeline, the company plans to execute its 1st phase in Q3 2022, where it will launch its B2C Fandifi platform with bespoke content and an open platform for gaming. In the last part of the year 2022, Fandifi will launch its B2C platform across other industries and will secure partnerships. The market is enormous and keeps growing. With an audience that needs to be more engaged, Fandifi makes content more social and engaging with Gamification through prediction and analytics. There is a decline in the 55 and 18-34 years old viewing Live TV. The young population watched 23.4% less live TV in 2020 vs.2019. Fandifi helps to close the gap between the viewer and the action, making every minute engaging.
“Sports leagues, especially Major League Baseball, are seeing declines in younger viewership. The change comes as people turn away from traditional TV viewing and toward social media, video games and streaming TV” – Wall Street Journal,
Management Overview
David Vinokurov (CEO)
David is a seasoned capital markets professional involved in numerous aspects of corporate management and deploying capital market strategies for publicly listed companies. David is a focused, determined, competent member of management and advisory boards of companies in the gaming, esports, igaming, technology, fintech, and natural resource sectors.
Renjun Bao Ph.D. (Advisory board)
Mr. Bao is a renowned thought leader with extensive sports industry knowledge in China and USA and has worked with many major international leagues. Mr. Bao currently serves as the Director of Business Development. He is a Senior Sports Reporter for Tencent Sports America. He is responsible for maintaining top-tier relations with major sports leagues for which Tencent has exclusive broadcast rights for the Chinese market.
Share Structure/Financials
For an emerging tech company, Fandifi has strong fundamentals. On the balance sheet side, the company has $4M in total assets with $2.5M in cash and cash equivalents. The company also has no debt, which leads Fandifi to have a clean balance sheet. In the three months ended April 30, the company’s most significant expenses were the platform and development costs which represented $319k.
About the share structure, the company has 82M shares outstanding, with 25% held by management, board & key investors. Fandifi also has 35M warrants which could bring $10M if they are all exercised (min. price: $0.10 and max. price: $0.50), and 8.5M options representing $2.1M in cash (min. price: $0.09 and max price: $0.50). Fully diluted, there are 126M shares. If the company manages to increase its market cap and share price, it could enable Fandifi to exercise its warrants and options and have a healthy dilution. During the year 2022, no trades on the market have been made by insiders.
Because the company has an emerging business, the ongoing concern written in the financial statement explains the company still couldn’t finance day-to-day activities through operations. The company’s continuation as a going concern is dependent upon the successful results from the development and monetization of the Company’s Entertainment Platform for sports and esports superfan engagement and the related mobile applications and its ability to attain profitable licensing and advertising-based operations and generate funds from and/or raise equity capital or borrowings sufficient to meet current and future obligations, all of which are uncertain. If, as mentioned above, the company plans to cover the operating costs over the next twelve months from related parties, the exercise of stock options, and warrants, the company could also get funds generated from private placements.
Share Movement
Fandifi’s stock price is currently worth $0.12 for a $9.5M market cap. If the stock went to a 52-week high of $0.25 on April 4, it went on a continuous downtrend to reach its 52-week low of $0.075 on June 30.
About stock performance, it just gave a positive return on investment if you invested a month ago (43.7%). If you bought it other times, the stock gave -45% Year-over-Year and -28% in the last three months.
The technical side indicates the stock is currently a BUY, with 10 Buy, 11 Neutral, and five sell signals. RSI and RSI-based MA data indicate the stock is neither overbought nor oversold (30 and under, 70 and above) as these data represent 53 and 52. Its Moving Averages show the stock is in a downtrend with its Simple MA (200) worth $0.145and above its Simple MA (50) worth $0.105.
Bottom Line
-Fandifi is building a crowd-based and system-generated prediction fan engagement platform;
-The company has $2.5M in cash, has 25% held by insiders & key investors, and is currently a BUY according to technical;
-It has options and warrants which could help the company to fund its operations if exercised;
-Mr. Bao is part of the advisory board; he is a renowned thought leader with extensive sports industry knowledge in China and USA;
-Fandifi is traded in Canada, the USA, and Germany (CSE: FDM) (OTCQB: FDMSF) (FSE: TQ4).
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he is head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
All Articles
The latest
INVESTMENT: THIS AI FIRM JUST RELEASED SOME GAME-CHANGING NEWS
Alset Capital Inc. (TSXV: KSUM) : Innovative Advancements Together with Nvidia
Discover The Phillips Township Property from Golden Rapture (CSE:GLDR)
Subscribe
©2024 10xAlerts